“…Interestingly, RyR2, a target of carvedilol, is abundantly expressed in both the heart and the brain (Furuichi et al, 1994;Giannini et al, 1995;Murayama and Ogawa, 1996;Bers, 2002). In particular, RyR2 is abundantly expressed in the hippocampus and cortex, which are the regions most vulnerable to damage caused by AD (Yao et al, 2020;Hiess et al, 2022). Increasing evidence suggests that the expression and function of RyR2 are upregulated in animal models of familial AD (FAD) and in human AD patients (Kelliher et al, 1999;Smith et al, 2005;Bruno et al, 2012;Oules et al, 2012;Chakroborty and Stutzmann, 2014;Lacampagne et al, 2017;SanMartin et al, 2017;Stutzmann, 2021).…”